NEOCRTEC5010

NCT01216527 📎

Regimen

Experimental
neoadjuvant vinorelbine/cisplatin + 40 Gy RT + surgery
Control
surgery alone

Population

Potentially resectable thoracic ESCC clinical stage T1-4N1M0 or T4N0M0

Key finding

mOS 100.1 vs 66.5 mo (HR 0.71, P=.025); pCR 43.2%; R0 98.4% vs 91.2%. DFS HR 0.58 (P<.001).

Source: PMID 30089078

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.111)